ArticleOxford medical case reports2026
Long-term complete radiological response to immunotherapy in a patient with metastatic NSCLC and active rheumatoid arthritis.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of immune checkpoint inhibitors (ICIs) in patients with autoimmune diseases (AIDs) is challenging due to the risk of immune-related adverse events and disease flares. These patients are routinely excluded from clinical trials, leaving limited evidence to guide practice. We report a 70-year-old woman with metastatic non-small cell lung cancer (NSCLC) and active rheumatoid arthritis (RA) receiving infliximab and methotrexate. Initial treatment with platinum-based chemotherapy excluded ICIs. After disease progression, pembrolizumab was introduced with chemotherapy following multidisciplinary discussion. The patient achieved a complete radiological response without RA flare, completed two years of pembrolizumab in March 2022, and remains in remission as of August 2025. This case highlights that ICIs can be used safely in selected patients with active AID, preserving functional status and quality of life. Prospective studies in this population are needed to refine risk-benefit assessment and optimise patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.